Home Tools
Log in
Cart

Search Result

Search Results for " chronic myelogenous leukemia (cml) "

8

Compounds

Cat No. Product Name Synonyms Targets
T1803 GNF-5 GNF 5 SARS-CoV , Bcr-Abl
GNF-5 is a specific non-ATP competitive inhibitor of Bcr-Abl (IC50: 0.22±0.1 uM, Wild-type Abl). It is an analog of GNF-2 with improved pharmacokinetic properties.
T3196 GNF-7 GNF7 Bcr-Abl , ACK , AChR
GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.
T22553 Adaphostin 1-Adamantyl 4-((2,5-Dihydroxybenzyl)Amino)Benzoate,NSC 680410 Bcr-Abl
Adaphostin (NSC-680410) is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM.
T16545 Pivanex Pivalyloxymethyl butyrate,AN-9 Apoptosis , HDAC , Bcr-Abl
Pivanex (Pivalyloxymethyl butyrate) is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.
T26625 AN-019 NRC-AN-019,NRC-019 Bcr-Abl
AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.
T72958 BCR-ABL-IN-7 Bcr-Abl
BCR-ABL-IN-7 is a WT and T315I mutant ABL kinase inhibitor.BCR-ABL-IN-7 potently inhibits WT and T315I mutant ABL kinase activity.BCR-ABL-IN-7 can be used in chronic myelogenous leukemia (CML) research.
T22859 Imatinib hydrochloride Others
Imatinib is a multi-target inhibitor of v-Abl, c-Kit, and PDGFR (IC50: 0.6 μM, 0.1 μM, and 0.1 μM, respectively). Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs), and...
T71313 BVB-808
BVB-808 is a selective Jak2 type 1 inhibitor. Janus kinases are critical components of signaling pathways that regulate hematopoiesis. Mutations of the non-receptor tyrosine kinase JAK2 are found in many BCR-ABL-negative...
TargetMol